Recipe For Doubling Innovative Medicines Includes New Approval Pathway, FDA Management Changes
Executive Summary
Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.
You may also be interested in...
Antibiotic Development To Get Fresh Push, Not Fresh Ideas, From PCAST
Upcoming report from presidential advisors will endorse limited population approval, and government funding mechanisms as part of plan to fight resistance.
FDA, Uninvited To Congress’ PCAST Hearing, Blogs Its Accomplishments
Woodcock says “critical challenges” remain on implementing recommendations of President’s Council, but timing of statement could be signal to Congress: be careful what else you put on our plates.
Lagging CDER Review Divisions Could Learn From Oncology, Antiviral Offices
FDA’s drugs center should identify “best practices” in oncology and antiviral drug reviews that could be applied by less efficient review divisions, such as cardio/renal and neurology, authors of a Manhattan Institute report say.